ClinicalTrials.Veeva

Menu

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

Otsuka logo

Otsuka

Status and phase

Completed
Phase 3

Conditions

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Treatments

Drug: Tolvaptan Oral Tablet

Study type

Interventional

Funder types

Industry

Identifiers

NCT03048747
156-14-003
JapicCTI-173512 (Other Identifier)

Details and patient eligibility

About

The objective of this study is to investigate the efficacy and safety of tolvaptan based on the change in serum sodium concentration following administration of tolvaptan oral tablets at 7.5 to 60 mg/day for up to 30 days in patients with hyponatremia in the SIADH.

Enrollment

16 patients

Sex

All

Ages

20 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects with a definite diagnosis of SIADH in reference to "Diagnostic and Treatment Manual of the Hypersecretion of Vasopressin (SIADH), Revised in 2011"
  • Subjects who have been on fluid restriction for at least 7 consecutive days at the time of informed consent and who are showing no improvement of hyponatremia at the time of the screening examination

Exclusion criteria

  • Subjects who have transient hyponatremia induced by drug administration
  • Subjects who are unable to sense thirst or who have difficulty with fluid intake
  • Subjects with urinary tract obstruction
  • Subjects who have participated in any other clinical trial within 30 days prior to informed consent
  • Subjects with serum sodium concentration of <120 mEq/L associated with neurologic impairment, including apathy, confusion, or seizures

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

16 participants in 1 patient group

Tolvaptan
Experimental group
Description:
Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
Treatment:
Drug: Tolvaptan Oral Tablet

Trial documents
2

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems